(Q33738724)

29 July 2017

title

Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials (English)

1 reference

idiopathic pulmonary fibrosis

29 July 2017

main subject

phase III clinical trial

0 references

pulmonary fibrosis

1 reference

based on heuristic

inferred from title

1 reference

3

Kevin J Anstrom

1 reference

29 July 2017

7

Fernando J Martinez

1 reference

29 July 2017

Ganesh Raghu

1

1 reference

29 July 2017

Harold R Collard

2

1 reference

29 July 2017

Kevin R Flaherty

4

1 reference

29 July 2017

Thomas R Fleming

5

1 reference

29 July 2017

Talmadge E King

6

1 reference

29 July 2017

Kevin K Brown

8

1 reference

29 July 2017

language of work or name

English

0 references

publication date

13 April 2012

1 reference

American Journal of Respiratory and Critical Care Medicine

29 July 2017

published in

1 reference

29 July 2017

volume

185

1 reference

29 July 2017

issue

10

1 reference

29 July 2017

page(s)

1044-1048

1 reference

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Addressing missing data in clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Strategies for treating idiopathic pulmonary fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Pirfenidone in idiopathic pulmonary fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Acute exacerbations of idiopathic pulmonary fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Incidence and prevalence of idiopathic pulmonary fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

British Thoracic Society Study on cryptogenic fibrosing alveolitis: Response to treatment and survival

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

High-dose acetylcysteine in idiopathic pulmonary fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Surrogate end points in clinical trials: are we being misled?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448580

Clinical significance of histological classification of idiopathic interstitial pneumonia

21 June 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201201-0006PP

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201201-0006PP

Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201201-0006PP

Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201201-0006PP

Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201201-0006PP

Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201201-0006PP

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201201-0006PP

Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201201-0006PP

A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201201-0006PP

10.1164/RCCM.201201-0006PP

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference

29 July 2017

1 reference